Key Research Findings Prolonged IGF-1R Signaling Reduced IGFBP binding extends the circulating half-life from approximately 20 minutes (native IGF-1) to several hours, enabling sustained PI3K/Akt and MAPK pathway activation in preclinical models Skeletal Muscle Hypertrophy Rodent studies demonstrate that IGF-1 LR3 administration promotes muscle protein synthesis and satellite cell activation via mTOR signaling Cell Culture Applications IGF-1 LR3 is routinely used as a serum-free media supplement to support cell growth, replacing insulin in many protocols due to its superior stability and potency Metabolic Research Preclinical studies indicate IGF-1 LR3 enhances glucose uptake in muscle tissue, making it a subject of investigation in metabolic signaling research Anti-Apoptotic Properties In vitro evidence suggests IGF-1 LR3 protects multiple cell types from apoptosis through upregulation of Bcl-2 family pro-survival factors Specifications Reported Side Effects in Research Hypoglycemia observed in animal models, particularly with concurrent insulin pathway activation Potential organ hypertrophy (intestinal, splenic) reported at high doses in rodent studies Localized edema and injection site swelling noted in preclinical protocols This product is intended strictly for laboratory and research purposes only
Individuals with a deficiency in vitamin B12 may experience symptoms such as fatigue, weakness, and changes in weight or metabolism
Always consult your doctor before making changes to your medication during pregnancy
Patients with T1D or T2D and CKD with established atherosclerotic cardiovascular disease should be treated with low-dose aspirin (75100mg/day) for secondary prevention
When in doubt, start with a reduced dose to assess response before committing to a full protocol
doi: 10.1111/j.1463-1326.2011.01364.x 109 DunganKMPovedanoSTForstTGonzlezJGGAtissoCSeallsWet al
